Compounds > tylophorinidine
Page last updated: 2024-12-08

tylophorinidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tylophorinidine: antileukemic agent from T. indica [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161749
CHEMBL ID250854
SCHEMBL ID19534276
MeSH IDM0100857

Synonyms (8)

Synonym
tylophorinidine
CHEMBL250854 ,
bdbm50213931
(13as,14s)-3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizine-6,14-diol
dibenzo(f,h)pyrrolo(1,2-b)isoquinoline-6,14-diol, 9,11,12,13,13a,14-hexahydro-3,7-dimethoxy-, (13as-trans)-
32523-69-6
DTXSID20186239
SCHEMBL19534276
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription factor AP-1Homo sapiens (human)IC50 (µMol)0.06500.00790.39202.0300AID308180
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IITranscription factor AP-1Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor AP-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTranscription factor AP-1Homo sapiens (human)
release from viral latencyTranscription factor AP-1Homo sapiens (human)
cellular response to reactive oxygen speciesTranscription factor AP-1Homo sapiens (human)
response to endoplasmic reticulum stressTranscription factor AP-1Homo sapiens (human)
positive regulation of apoptotic processTranscription factor AP-1Homo sapiens (human)
negative regulation of DNA bindingTranscription factor AP-1Homo sapiens (human)
negative regulation by host of viral transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation by host of viral transcriptionTranscription factor AP-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor AP-1Homo sapiens (human)
SMAD protein signal transductionTranscription factor AP-1Homo sapiens (human)
cellular response to cadmium ionTranscription factor AP-1Homo sapiens (human)
integrated stress response signalingTranscription factor AP-1Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTranscription factor AP-1Homo sapiens (human)
positive regulation of DNA-templated transcription initiationTranscription factor AP-1Homo sapiens (human)
regulation of cell population proliferationTranscription factor AP-1Homo sapiens (human)
regulation of cell cycleTranscription factor AP-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingTranscription factor AP-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor AP-1Homo sapiens (human)
DNA bindingTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor AP-1Homo sapiens (human)
RNA bindingTranscription factor AP-1Homo sapiens (human)
GTPase activator activityTranscription factor AP-1Homo sapiens (human)
protein bindingTranscription factor AP-1Homo sapiens (human)
enzyme bindingTranscription factor AP-1Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor AP-1Homo sapiens (human)
cAMP response element bindingTranscription factor AP-1Homo sapiens (human)
identical protein bindingTranscription factor AP-1Homo sapiens (human)
ubiquitin-like protein ligase bindingTranscription factor AP-1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingTranscription factor AP-1Homo sapiens (human)
R-SMAD bindingTranscription factor AP-1Homo sapiens (human)
general transcription initiation factor bindingTranscription factor AP-1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTranscription factor AP-1Homo sapiens (human)
transcription factor bindingTranscription factor AP-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nuclear chromosomeTranscription factor AP-1Homo sapiens (human)
nucleusTranscription factor AP-1Homo sapiens (human)
nucleoplasmTranscription factor AP-1Homo sapiens (human)
transcription factor AP-1 complexTranscription factor AP-1Homo sapiens (human)
RNA polymerase II transcription regulator complexTranscription factor AP-1Homo sapiens (human)
chromatinTranscription factor AP-1Homo sapiens (human)
euchromatinTranscription factor AP-1Homo sapiens (human)
transcription regulator complexTranscription factor AP-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID308174Cytotoxicity against PANC1 cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
AID308175Antitumor activity against HepG2 cells xenografted nude mouse at 9 mg/kg, ip twice per day on every third day for four cycles2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
AID308173Cytotoxicity against HepG2 cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
AID308180Inhibition of AP1-mediated gene transcription in HepG2 cells by luciferase reporter gene assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
AID308181Down regulation of cyclin D1 expression in HepG2 cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
AID308178Inhibition of NF-kappaB-mediated gene transcription in HepG2 cells by luciferase reporter gene assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
AID308179Inhibition of CRE-mediated gene transcription in HepG2 cells by luciferase reporter gene assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's3 (33.33)18.2507
2000's4 (44.44)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
palmitic acid
Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.		2.0310long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
dinitrofluorobenzene
Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.		210C-nitro compound;
organofluorine compound		agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		210isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.0310D-glucopyranoseepitope;
mouse metabolite
tubulosine
tubulosine: indole derivative of main alkaloids of ipecac; RN given refers to cpd with unspecified isomeric designation; structure. tubulosine : A member of the class of beta-carbolines that is tubulosan bearing methoxy groups at positions 10 and 11 and a hydroxy group at the 8' position.		710beta-carbolines;
isoquinoline alkaloid;
isoquinolines;
phenols;
secondary amino compound;
tertiary amino compound
tylophorine
tylophorine: phenanthroindolizidine alkaloid		2.4220organic heteropentacyclic compound;
organonitrogen heterocyclic compound
dcb 3503
[no description available]		2.0310
pergularinine
pergularinine: RN refers to (13aS-cis)-isomer; structure in first source		2.9140
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.4420
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Lymphoid Leukemia
[description not available]		01.9910
Granulocytic Leukemia, Chronic
[description not available]		01.9910
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		01.9910
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		01.9910
Benign Neoplasms
[description not available]		0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		0210
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		0210
Delayed Hypersensitivity
[description not available]		0210